HK1212258A1 - Levodopa formulations for rapid relief of parkinsons disease - Google Patents

Levodopa formulations for rapid relief of parkinsons disease

Info

Publication number
HK1212258A1
HK1212258A1 HK16100409.7A HK16100409A HK1212258A1 HK 1212258 A1 HK1212258 A1 HK 1212258A1 HK 16100409 A HK16100409 A HK 16100409A HK 1212258 A1 HK1212258 A1 HK 1212258A1
Authority
HK
Hong Kong
Prior art keywords
parkinsons disease
rapid relief
levodopa formulations
levodopa
formulations
Prior art date
Application number
HK16100409.7A
Other languages
English (en)
Chinese (zh)
Inventor
Martin Freed
Richard Batycky
Michael M Lipp
Original Assignee
Civitas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Civitas Therapeutics Inc filed Critical Civitas Therapeutics Inc
Publication of HK1212258A1 publication Critical patent/HK1212258A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
HK16100409.7A 2012-10-22 2016-01-14 Levodopa formulations for rapid relief of parkinsons disease HK1212258A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261716740P 2012-10-22 2012-10-22
US201361813605P 2013-04-18 2013-04-18
US201361813725P 2013-04-19 2013-04-19
PCT/US2013/065838 WO2014066208A1 (en) 2012-10-22 2013-10-21 Levodopa formulations for rapid relief of parkinson's disease

Publications (1)

Publication Number Publication Date
HK1212258A1 true HK1212258A1 (en) 2016-06-10

Family

ID=50545142

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16100409.7A HK1212258A1 (en) 2012-10-22 2016-01-14 Levodopa formulations for rapid relief of parkinsons disease
HK16100641.5A HK1212623A1 (zh) 2012-10-22 2016-01-21 用於快速緩解帕金森病的左旋多巴製劑

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16100641.5A HK1212623A1 (zh) 2012-10-22 2016-01-21 用於快速緩解帕金森病的左旋多巴製劑

Country Status (18)

Country Link
US (1) US20150328175A1 (ru)
EP (2) EP3943080A1 (ru)
JP (2) JP2016500690A (ru)
KR (2) KR20210075224A (ru)
CN (2) CN104884046A (ru)
AU (3) AU2013334949B2 (ru)
BR (1) BR112015009088A2 (ru)
CA (1) CA2888994C (ru)
DK (1) DK2908805T3 (ru)
ES (1) ES2886529T3 (ru)
HK (2) HK1212258A1 (ru)
MX (2) MX2021014782A (ru)
NZ (1) NZ708414A (ru)
PL (1) PL2908805T3 (ru)
PT (1) PT2908805T (ru)
RU (2) RU2685718C2 (ru)
SG (2) SG11201503129RA (ru)
WO (1) WO2014066208A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2888979A1 (en) * 2012-10-22 2014-05-01 Civitas Therapeutics, Inc. Reducing inter-patient variability of levodopa plasma concentrations
WO2014074797A1 (en) 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
JP2017513866A (ja) * 2014-04-21 2017-06-01 サイヴィタス セラピューティックス,インコーポレイテッド パーキンソン病の運動症状変動の迅速な緩和
JP2021509676A (ja) * 2018-01-05 2021-04-01 インペル ニューロファーマ インコーポレイテッド 精密嗅覚装置によるレボドパ粉末の鼻腔内送達
KR20210034047A (ko) 2018-07-19 2021-03-29 임펠 뉴로파마 인코포레이티드 파킨슨 병 치료를 위한 레보도파 및 도파 데카르복실라아제 저해제의 기도 전달

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6514482B1 (en) 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
GB0027020D0 (en) * 2000-11-03 2000-12-20 Univ Manchester Treatment of movement disorders
ES2609482T3 (es) * 2002-03-20 2017-04-20 Civitas Therapeutics, Inc. Administración pulmonar de levodopa
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
GB2454480A (en) * 2007-11-07 2009-05-13 Vectura Group Plc Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders

Also Published As

Publication number Publication date
RU2019111096A (ru) 2020-10-12
BR112015009088A2 (pt) 2017-07-04
NZ708414A (en) 2018-11-30
RU2015119377A (ru) 2016-12-10
AU2013334949B2 (en) 2018-08-09
MX2015005038A (es) 2015-12-01
DK2908805T3 (da) 2021-09-13
RU2685718C2 (ru) 2019-04-23
KR20150102960A (ko) 2015-09-09
JP2018150339A (ja) 2018-09-27
EP2908805B1 (en) 2021-06-09
CN110812350A (zh) 2020-02-21
JP2016500690A (ja) 2016-01-14
US20150328175A1 (en) 2015-11-19
CA2888994A1 (en) 2014-05-01
AU2013334949A1 (en) 2015-06-11
CA2888994C (en) 2022-10-04
EP2908805A1 (en) 2015-08-26
AU2018253538B2 (en) 2020-08-20
PT2908805T (pt) 2021-09-10
ES2886529T3 (es) 2021-12-20
EP2908805A4 (en) 2016-07-06
SG10201804985QA (en) 2018-07-30
HK1212623A1 (zh) 2016-06-17
PL2908805T3 (pl) 2021-12-27
AU2018253538A1 (en) 2018-11-22
AU2020250325A1 (en) 2020-11-12
EP3943080A1 (en) 2022-01-26
MX2021014782A (es) 2023-03-23
KR20210075224A (ko) 2021-06-22
CN104884046A (zh) 2015-09-02
WO2014066208A1 (en) 2014-05-01
SG11201503129RA (en) 2015-05-28

Similar Documents

Publication Publication Date Title
HK1212701A1 (zh) 恩雜魯胺製劑
IL236211A0 (en) Adjustable shoe
HK1204755A1 (en) Stretchable insole
EP2814487A4 (en) BENDAMUSTIN FORMULATIONS
HK1204973A1 (en) Diclofenac formulations
FI2827862T3 (fi) Bendamustiinin formulaatioita
IL250725B (en) Difluorolactam formulations for ep4-mediated bone-related conditions and diseases
EP2861092A4 (en) ANKLE
EP2845501A4 (en) SHOE
HK1212623A1 (zh) 用於快速緩解帕金森病的左旋多巴製劑
EP2900059A4 (en) BOOTS FOR HOOF
AU347332S (en) Orthotic footwear
EP2921069A4 (en) SHOE SHAPE
GB201210530D0 (en) Extended release formulations
GB2504191B (en) Track-type sex aid
PL2710988T3 (pl) Wkładka do butów
GB201201805D0 (en) Speculum
GB201204645D0 (en) Treatment of disease
AU345091S (en) Shoe
AU345090S (en) Shoe
AU345089S (en) Shoe
AU345166S (en) Hoof boot
GB201203658D0 (en) Shoe manipulator
GB201221268D0 (en) Novel speculum
GB201206178D0 (en) Formulations